Cardiology

While social media and technology have allowed greater sharing of ideas and knowledge, they have also become a major source of misinformation. In this column, Dr. Weiss reflects on practicing during the age of misinformation.

A high fasting insulin level trajectory was associated with psychosis, while puberty-onset BMI increase was linked to depression.

A phase 2 study suggests treating the common diabetes comorbidity may be capable with the monoclonal antibody.

Results from a systematic review and meta-analysis of more than 50 studies assessing cardiovascular risk with levels of abdominal aortic calcification indicate increased AAC was linked to 80% increase in risk of cardiovascular events and cardiovascular death.

An analysis of data from the UK Biobank cohort offers an overview of the risk reduction for cardiovascular disease derived from various levels and measurements of physical activity.

Data from questionnaires given to type 1 and type 2 diabetes patients from an outpatient clinic is providing insight into how the COVID-19 pandemic has impacted diabetes management.

A quality improvement study conducted at a trio of Penn Medicine hospitals suggests changing cardiac rehabilitation referrals from an opt-in to an opt-out decision in their EHR could drastically improve referral rates.

The SOLOIST-WHF trial indicates that SGLT2 inhibition may lead to an overall reduction in cardiovascular-related deaths and hospitalizations.

An analysis of nearly 100k people from the UK Biobank study suggests there was no upper threshold on the reduction in risk of cardiovascular disease derived from physical activity.

An analysis of more than 100k people from five community-based cohorts indicates consuming one alcoholic drink per day could increase risk of atrial fibrillation by 16%, while consuming four per day increased risk by 47%.

A conversation on how associations between the chronic conditions have become better understood in 10 years.

In this column, Dr. Paul Thompson offers his perspective on the use of digoxin and explains why he has maintained use in certain patient populations despite its waning popularity in recent years.

An analysis by clinicians from Beth Israel Deaconess Medical Center provides an overview of the increase in cardiac deaths occurring as a result of avoiding emergency departments during the COVID-19 pandemic.

A recent study of more than 3000 patients found 13 novel and significant associations with cerebrovascular disease and transient cerebral ischemia.

If approved, the treatment would be the first SGLT2 inhibitor for patients with chronic kidney disease.

Results of the REPLACE COVID trial offer clinicians an opportunity to better understand the impact of discontinuing therapy with ACEs or ARBs.

A study from UCL is providing clinicians with an estimate of excess cardiac deaths that occurred as a result of nonattendance to emergency department visits during the March 2020 peak of the pandemic.

A randomized trial provides further insight into the effects of intensive lifestyle interventions on coronary plaque progression in patients with nonobstructive coronary artery disease.

A lipidologist from Connecticut describes his experience during the COVID-19 pandemic and explains why he sees getting the vaccine as his "biggest contribution" to healthcare during the pandemic.

Further investigation needs to be done to determine whether this increase is due to the effects of lockdowns or the virus itself.

A lipidologist from Connecticut describes his experience during the COVID-19 pandemic and explains why he sees getting the vaccine as his "biggest contribution" to healthcare during the pandemic.

The US and the world must appreciate the role of the pharmaceutical industry who are rescuing the world from COVID-19—the medical breakthrough of our lifetime.

The burden of cardiovascular disease is particularly high in African Americans, a population that typically faces health disparities.

A single-center trial from Europe is comparing plaque progression using CTA scans of patients randomized to intensive lifestyle intervention versus optimized medical therapy alone.

Patients who continue RAS therapy had a lower risk of kidney replacement therapy.